CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification.

导出 LinkOut

翻译打印收藏纠错

作者： Jae Young,Hur ^[1] ; Hyeong Ryul,Kim ^[2] ; Jung Yeon,Lee ^[3] ; Sojung,Park ^[4] ; Ji An,Hwang ^[5] ; Woo Sung,Kim ^[5] ; Shinkyo,Yoon ^[5] ; Chang-Min,Choi ^[6] ; Jin Kyung,Rho ^[5] ; Jae Cheol,Lee ^[6]

作者单位： Asan Institute for Life Sciences, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea. ^[1] Lung Cancer Center & Department of Pathology, Konkuk University Medical Center, Seoul, South Korea. ^[2] Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea. ^[3] Department of Internal Medicine, Graduate School, Chungbuk National University, Cheongju, South Korea. ^[4] Department of Pulmonology and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea. ^[5] Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. ^[6] Department of Convergence Medicine, Asan Medical Center, College of Medicine, University of Ulsan, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. jkrho@amc.seoul.kr. ^[7] Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. jclee@amc.seoul.kr. ^[8]

关键词 CDK7 SOX2 Squamous cell lung cancer (SCC)THZ1 Transcriptional addiction